Miga Health

Miga Health is a heart health platform focused on preventing the next million heart attacks and strokes.

https://www.migahealth.com/

Miga Health is an end-to-end vertical treatment platform for hypertension (high blood pressure) centered around the consumer. Miga was founded by Dr. Jarrad Aquirre (Yale undergrad, Rhodes Scholar, Stanford MD / MBA) and Dre Limberopoulos (previous founder of a wearable tech company and an early employee at TrialSpark) in Q4 2021.

Miga Health is a digital-first provider of hypertension-related care. Consumers sign up for a monthly subscription to Miga, and will be able to purchase add-ons (e.g., medication and quarterly lab check-ins). In return, Miga will send the consumer a free cuff for measuring blood pressure and plans to offer additional services, including a virtual community, personalized coaching, gamified collection of blood pressure (BP) readings, data shared with a PCP or physician, medication management, and fingerstick labs. 

Investment Thesis

  • Large, fragmented market with no scaled competitive platform: >116 million American adults have some form of hypertension, with 37 million having stage 2 hypertension, which requires medication and would be Miga’s serviceable addressable market. 
  • Chronic condition fit for at-home offering: Hypertension is a chronic condition that requires consistent monitoring that can be done just as effectively at-home as in an in-clinic setting.
  • Increasing consumer adoption of at-home healthcare services: There is increasing precedent for consumers trusting digital health startups, with hypertension having the unique benefit of being very important over the long run, yet fairly low-risk in the short-run, such that consumers are willing to try a new solution.
  • Unique alignment of incentives:  Miga offers a unique opportunity to align the incentives of all participants: patients get quality care at a relatively low price point, physicians benefit from outsourcing relatively “low-hanging fruit” and free up time to focus on more acute patients, employers and payers benefit from a high-quality, relatively low-cost solution that will have a significant ROI down the road by preventing strokes and heart attacks. 
  • Clear path to an expanded market / additional revenue opportunities: While monitoring patient data, Miga will capture valuable data outside of a controlled lab environment, which has become increasingly attractive to pharma companies and would be a significant potential revenue stream. Furthermore, Miga could expand into additional products and services focused on obesity, high cholesterol, and diabetes for its existing customer base as these conditions often co-occur with hypertension. 

Industry/Context

Almost half of all adults in the U.S. (>116 million) have some form of hypertension. Approximately 37 million adults have stage 2 hypertension, defined as blood pressure of 140/90 mmHg or higher, and are usually recommended to take medication along with lifestyle changes. It is estimated that approximately $130-$200 billion is spent on hypertension annually in the U.S. Expanding to include the larger cardiovascular market, it is estimated that cardiovascular issues cost the U.S. ~$360 billion annually.

Founders

Jarrad Aguirre, MD

Jarrad Aguirre, MD

Yale (BS, Biology), University of Oxford (MPhil, Medical Anthropology), Stanford University School of Medicine (MD), Stanford University Graduate School of Business (MBA)

EXPERIENCE
No items found.
Andreas Limberopoulos

Andreas Limberopoulos

Monash University (BSE, Bachelor of Software Engineering)

EXPERIENCE
No items found.

What we like

Cardiovascular disease is one of the largest and most expensive diseases in the U.S., causing 1 in 3 deaths and costing society upwards of $360 billion annually. However, ~80% of premature heart attacks and strokes are preventable. Hypertension is the foremost modifiable risk for cardiovascular disease and is highly prevalent. The current solution for treating hypertension is fragmented, inconvenient, and leaves the onus on the patient, who must actively show up in person, be diligent about recording their blood pressure daily with no short-term incentives, coordinate sporadic check-ins with their doctor, visit labs for blood tests, etc. We see Miga Health in the broader context of our theme around patient-centric disruptive solutions for chronic disease.